Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

MEG and Aphantasia

NCT07630324 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-06-10

Condition(s) studied

Aphantasia

Investigational drug(s) / intervention(s)

MEGMRIVividness of motor imagery questionnaire - second version

MEG: Within a single session, measure of brain oscillations during four types of covert actions (motor imagery, action observation, action language and movement preparation).

MRI: Anatomical MRI, performed once

Vividness of motor imagery questionnaire - second version: Before MEG and MRI, measure of vividness for internal visual imagery, external visual imagery and kinesthetic imagery (for 12 actions).

Study summary

Covert actions are cognitive processes that involves the motor system. They include motor imagery, movement preparation, action observation or action language. They imply mental simulations, based on activations of neural networks, involved in specific operations such as perceiving or acting. These mental phenomena have intrigued and still intrigue philosophers, psychologists, and neuroscientists, as they are complex and introspective processes, which play a major role in human cognition.

To decipher similarities and differences between these types of covert actions, the investigators will focus on persons living with aphantasia, which is a neurocognitive specificity present in a small proportion of the population (5 to 8%). Aphantasia is characterized by the alteration or the absence of explicit mental representations.

This population offers an ideal testbed to disentangle the involvement of cognitive and motor processes in different forms of covert actions.

By means of magnetoencephalography, this study aims to identify and compare brain patterns and their temporal dynamics in alpha and beta bands during covert actions in two groups of healthy volunteers: aphantasics and non-aphantasics (i.e., having a non-altered imagery capacity).

If covert actions indeed share brain networks, the investigators expect aphantasics to present reduced neural and behavioral activation during the explicit (i.e., motor imagery) and implicit (movement preparation, action language and action observation) forms of covert actions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18 to 60 years * Willing to actively participate in the study * Having signed an informed consent form to participate in the study Inclusion Failure Criteria: Identification of individuals with and without aphantasia based on responses to a questionnaire validated in the literature: Vividness of Movement Imagery Questionnaire, second version (VMIQ-2): Scores required for inclusion in the aphantasic group * VMIQ-2: internal visual imagery score = 55-60 * VMIQ-2: kinesthetic imagery score = 55-60 Scores required for inclusion in the non-aphantasic group * VMIQ-2: internal visual imagery score = 20-36 * VMIQ-2: kinesthetic imagery score = 20-36 Exclusion Criteria: * Neurological or psychiatric disorders * History of neurological or psychiatric disorders * Sleep disorders that may affect data variability or quality, or participant cooperation and retention, as assessed by the principal investigator or co-investigator during the inclusion interview * Volunteers presenting standard contraindications to MEG and MRI examinations: * Presence of incompatible metal in the body (pacemaker, implanted pump including insulin pump, neurostimulator, cochlear implants or other hearing devices, metallic prosthesis, intracerebral/surgical aneurysm clips, implantable defibrillator, ferromagnetic foreign bodies in the eyes or brain in the upper body, ventriculoperitoneal shunt valves, dental braces or steel posts in root canals, ferromagnetic foreign bodies in the upper body) * Claustrophobia * Pregnant or breastfeeding women * Individuals under guardianship, curatorship, or legal protection * Individuals deprived of liberty * Individuals undergoing psychiatric care * Individuals admitted to a health or social institution for reasons other than clinical research * Individuals not affiliated with a social security system or not beneficiaries of such a system

Primary outcome measure(s)

  • Whole-brain power of beta band (Tesla2) — During MEG recording
    Power of beta band with whole brain analysis during each of the four covert actions (motor imagery, action observation, movement preparation and action language).

Trial sites (1)

FacilityCityRegionStatus
CERMEP Bron France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07630324 on ClinicalTrials.gov ↗ ← All trials in France